Full Press Release Details
and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
conference call and webcast at 4:30PM EDT
YORK, November 3, 2021 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage
medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company
today announced that the companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT. During
the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the companies, will provide a business update including an overview
of the Company's near-term milestones and growth strategy. In addition, Dennis McGrath, the companies' Chief Financial Officer,
will discuss the companies' third quarter 2021 financial results.
access the conference call, U.S.-based listeners should dial 877-407-3982 and international listeners should dial 201-493-6780. All listeners
should provide the operator with the conference call name "PAVmed, Inc. Business Update Conference Call" to join. Individuals
interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Company's
website at www.pavmed.com.
the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within
the U.S. or 412-317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 1374402.
The webcast will be available for replay on the investor relations section of the Company's website at www.pavmed.com.
Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing
unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its
major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the first and only commercial tools for widespread early detection of
esophageal precancer and cancer - the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell
Collection Device. Its GI Health division also includes the complementary EsoCure Esophageal Ablation Device with Caldus
Technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular
access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Its
Minimally Invasive Interventions division markets its CarpX Minimally Invasive Device for Carpal Tunnel Syndrome. Other
divisions include Infusion Therapy (PortIO Implantable Intraosseous Vascular Access Device and NextFlo Intravenous Infusion
Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support).
our videos on YouTube.
Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:
PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at
risk of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples
collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and
only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through
early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test
(LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was
granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials
to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure
for EsoGuard testing.
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed's management,
are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties
that may cause such differences include, among other things, the ability to complete the initial public offering of Lucid; volatility
in the price of PAVmed's common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time required advance PAVmed's products to regulatory submission;
whether regulatory authorities will be satisfied with the design of and results from PAVmed's preclinical studies; whether and
when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized;
our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other
regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business.
The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company's financial and
operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response.
New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible
to predict accurately and many of them are beyond PAVmed's control. For a further list and description of these and other important
risks and uncertainties that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's
most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item
1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims
any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in
events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results
will differ from those contained in the forward-looking statements.